Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
BioNTech SE - American Depositary Shares
(NQ:
BNTX
)
88.85
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 18, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about BioNTech SE - American Depositary Shares
< Previous
1
2
...
26
27
28
29
30
31
32
33
34
...
72
73
Next >
Is BioNTech a Good Long-Term Buy?
↗
October 27, 2022
BioNTech has a burgeoning oncology portfolio up its sleeve.
Via
The Motley Fool
Are Pfizer and Moderna Stocks Buys With a Potential COVID Surge Coming?
↗
October 26, 2022
There's still considerable near-term uncertainty for both of these vaccine makers.
Via
The Motley Fool
JP Morgan Maintains Neutral Rating for BioNTech: Here's What You Need To Know
↗
October 24, 2022
JP Morgan has decided to maintain its Neutral rating of BioNTech (NASDAQ:BNTX) and lower its price target from $183.00 to $132.00. Shares of BioNTech are trading down 0.68% over the last 24 hours, at...
Via
Benzinga
BioNTech to Report Third Quarter 2022 Financial Results and Operational Update on November 7, 2022
October 24, 2022
From
BioNTech SE
Via
GlobeNewswire
Moderna, Amazon, Tesla, And Other Big Gainers From Friday
↗
October 24, 2022
U.S. stocks closed higher on Friday, with the Dow Jones gaining around 750 points. Here is the list of some big stocks recording gains in the previous session.
Via
Benzinga
Why Huntington Bancshares Shares Surged Around 10%; Here Are 72 Biggest Movers From Friday
↗
October 24, 2022
Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) jumped 89.3% to close at $58.92 on Friday.
Via
Benzinga
Why Novavax Stock Rose 12.57% on Friday
↗
October 21, 2022
Investors did an about-face after the stock slumped earlier in the week.
Via
The Motley Fool
Why Are Vaccine Stocks MRNA, PFE, BNTX, NVAX Up Today?
↗
October 21, 2022
Vaccine stocks are flying higher on Friday on word that Pfizer will quadruple the price of its Covid-19 vaccine. Will others follow suit?
Via
InvestorPlace
Why Boston Beer Shares Are Trading Higher? Here Are 52 Stocks Moving In Friday's Mid-Day Session
↗
October 21, 2022
Gainers Altamira Therapeutics Ltd. (NASDAQ: CYTO) surged 67% to $0.5484 after the company announced divestiture of its inner ear development assets.
Via
Benzinga
Twitter Rebuffs Elon Musk Layoff Plans Report, Toyota Cuts 2023's Production Target, Vaccine Makers Expect 3x Price Increase In COVID-19 Shot: Top Stories Friday, Oct. 21
↗
October 21, 2022
Bloomberg
Via
Benzinga
Vaccine Makers Mull Price Increase For COVID-19 Boosters Amid Falling Demand
↗
October 21, 2022
Via
Benzinga
Boston University's COVID-19 Created In Lab Research Comes Under Scrutiny
↗
October 20, 2022
Boston University created an artificial form of COVID-19 in a laboratory. Now, U.S. health officials have launched an inquiry into a controversial study. The Boston University research was designed to...
Via
Benzinga
Why Moderna Stock Dropped Today
↗
October 19, 2022
Competition is intensifying.
Via
The Motley Fool
Why Novavax Stock Couldn't Win on Wednesday
↗
October 19, 2022
FDA authorization isn't necessarily a slam dunk for a company.
Via
The Motley Fool
European Advisory Committee Backs Pfizer/BioNTech's COVID Shot For Younger Kids
↗
October 19, 2022
Via
Benzinga
Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 6 Months to less than 5 Years in the European Union
October 19, 2022
From
BioNTech SE
Via
GlobeNewswire
Why BioNTech SE And Novavax Shares Are Diving
↗
October 18, 2022
BioNTech SE - ADR (NASDAQ: BNTX) and Novavax, Inc. (NASDAQ: NVAX) shares are trading lower by 4.07% to $133.28 and 7.68% to $18.76, respectively, ahead of the close of Tuesday's session. Vaccine stock
Via
Benzinga
3 Supercharged Dividend Stocks to Buy if There's a Stock Market Sell-Off
↗
October 16, 2022
All three of these medical stocks offer a high-yield dividend.
Via
The Motley Fool
Bulls And Bears Of The Week: Amazon, Tesla, Apple, Meta And Why An Analyst Is Turning Less Positive On 2 Legacy Automakers
↗
October 15, 2022
Benzinga examined the prospects for many investors' favorite stocks over the past week — here's a look at some of our top stories.
Via
Benzinga
Why Novavax Stock Had an Ugly Friday
↗
October 14, 2022
Investors ding the biotech's shares one day after it reported quite good news about an experimental vaccine.
Via
The Motley Fool
Pfizer/BioNTech's Updated Omicron Adapted COVID-19 Shot Increases Neutralizing Antibodies Above Pre-Booster Levels
↗
October 13, 2022
Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ:
Via
Benzinga
Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older
October 13, 2022
From
BioNTech SE
Via
GlobeNewswire
Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older
October 13, 2022
From
Pfizer Inc.
Via
Business Wire
These 2 Stocks Gave Investors a Nice Surprise Wednesday
↗
October 12, 2022
Markets moved slightly lower in advance of the latest data on inflation.
Via
The Motley Fool
Why Pfizer Partner BioNTech SE Shares Are Trading Higher
↗
October 12, 2022
BioNTech SE - ADR (NASDAQ: BNTX) shares are trading higher by 5.37% to $136.45 going into the close of Wednesday's trading session after the FDA granted Emergency Use Authorization to the company's...
Via
Benzinga
FDA Authorizes Pfizer/BioNtech's Updated COVID-19 Booster Shots For Kids 5-11 Years
↗
October 12, 2022
Via
Benzinga
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age
October 12, 2022
From
BioNTech SE
Via
GlobeNewswire
Moderna, BioNTech And Some Other Big Stocks Moving Higher On Wednesday
↗
October 12, 2022
U.S. stocks traded mostly higher, with the Dow Jones gaining more than 100 points on Wednesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age
October 12, 2022
From
Pfizer Inc.
Via
Business Wire
Is Pfizer Stock Still Worth Buying After the Pandemic?
October 12, 2022
Pharmaceutical giant Pfizer (NYSE: PFE) is literally synonymous with COVID-19 vaccines, and as a result, Pfizer stock continues to beat expectations.
Via
MarketBeat
< Previous
1
2
...
26
27
28
29
30
31
32
33
34
...
72
73
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.